David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
BMC Medical Ethics 8 (1):1-7 (2007)
Background HIV prevention research has been fraught with ethical concerns since its inception. These concerns were highlighted during HIV vaccine research and have been elaborated in microbicide research. A host of unique ethical concerns pervade the microbicide research process from trial design to post-trial microbicide availability. Given the urgency of research and development in the face of the devastating HIV pandemic, these ethical concerns represent an enormous challenge for investigators, sponsors and Research Ethics Committees (RECs) both locally and internationally. Discussion Ethical concerns relating to safety in microbicide research are a major international concern. However, in the urgency to develop a medically efficacious microbicide, some of these concerns may not have been anticipated. In the risk-benefit assessment of research protocols, both medical and psycho-social risk must be considered. In this paper four main areas that have a potential for medical and/or psycho-social harm are examined. Male partner involvement is controversial in the setting of covert use of microbicides. However, given the long-term exposure of men to experimental products, this may be methodologically, ethically and legally important. Covert use of microbicides may impact negatively on relationship dynamics leading to psychosocial harm to varying extents. The unexpectedly high rates of pregnancy during clinical trials raise important methodological and ethical concerns. Enrollment of adolescents without parental consent generates ethical and legal concerns that must be carefully considered by RECs and trial sites. Finally, paradoxical outcomes in recent trials internationally have advanced the debate on the nature of informed consent and responsibility of researchers to participants who become HIV positive during or after trials. Summary Phase 3 microbicide trials are an undisputed research and ethical priority in developing countries. However, such trials must be conducted with attention to both methodological and ethical detail. It is imperative that guidelines are formulated to ensure that high ethical standards are maintained despite the scientific urgency of microbicide development. Given the controversy raised by emergent ethical issues during the course of microbicide development, it is important that international consensus is reached amongst the various ethics and regulatory agencies in developing and developed countries alike
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
R. Macklin (2010). Intertwining Biomedical Research and Public Health in HIV Microbicide Research. Public Health Ethics 3 (3):199-209.
S. Pomfret, Q. A. Karim & S. R. Benatar (2010). Inclusion of Adolescent Women in Microbicide Trials: A Public Health Imperative! Public Health Ethics 3 (1):39-50.
Udo Schuklenk (2007). HIV Vaccine Trials: Reconsidering the Therapeutic Misconception and the Question of What Constitutes Trial Related Injuries. Developing World Bioethics 7 (3).
Andrew Vallely, Shelley Lees, Charles Shagi, Stella Kasindi, Selephina Soteli, Natujwa Kavit, Lisa Vallely, Sheena McCormack, Robert Pool & Richard J. Hayes (2010). How Informed is Consent in Vulnerable Populations? Experience Using a Continuous Consent Process During the MDP301 Vaginal Microbicide Trial in Mwanza, Tanzania. BMC Medical Ethics 11 (1):10-.
Jeff Blackmer (2003). The Unique Ethical Challenges of Conducting Research in the Rehabilitation Medicine Population. BMC Medical Ethics 4 (1):1-6.
Keymanthri Moodley (2002). HIV Vaccine Trial Participation in South Africa - an Ethical Assessment. Journal of Medicine and Philosophy 27 (2):197 – 215.
Zaynab Essack, Jennifer Koen, Nicola Barsdorf, Catherine Slack, Michael Quayle, Cecilia Milford, Graham Lindegger, Chitra Ranchod & Richard Mukuka (2010). Stakeholder Perspectives on Ethical Challenges in Hiv Vaccine Trials in South Africa. Developing World Bioethics 10 (1):11-21.
Jennifer Koen, Zaynab Essack, Catherine Slack, Graham Lindegger & Peter A. Newman (2012). 'It Looks Like You Just Want Them When Things Get Rough': Civil Society Perspectives on Negative Trial Results and Stakeholder Engagement in HIV Prevention Trials. Developing World Bioethics 12 (3):138-148.
Lisa R. Stines & Norah C. Feeny (2008). Unique Ethical Concerns in Clinical Trials Comparing Psychosocial and Psychopharmalogical Interventions. Ethics and Behavior 18 (2 & 3):234 – 246.
S. Philpott, K. West Slevin, K. Shapiro & L. Heise (2010). Impact of Donor-Imposed Requirements and Restrictions on Standards of Prevention and Access to Care and Treatment in HIV Prevention Trials. Public Health Ethics 3 (3):220-228.
Catherine Slack, Ann Strode, Theodore Fleischer, Glenda Gray & Chitra Ranchod (2007). Enrolling Adolescents in HIV Vaccine Trials: Reflections on Legal Complexities From South Africa. BMC Medical Ethics 8 (1):1-8.
Ruth Macklin (2011). Ethical Challenges in HIV Microbicide Research: What Protections Do Women Need? International Journal of Feminist Approaches to Bioethics 4 (2):124-143.
Shawn H. E. Harmon (2008). Emerging Technologies and Developing Countries: Stem Cell Research Regulation and Argentina. Developing World Bioethics 8 (2):138-150.
Added to index2010-08-24
Total downloads7 ( #198,193 of 1,140,004 )
Recent downloads (6 months)1 ( #157,514 of 1,140,004 )
How can I increase my downloads?